Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency

INTRODUCTION: Individuals with proopiomelanocortin (POMC) or leptin receptor (LEPR) deficiency are young and experience severe obesity, hyperphagia, and comorbidities, which can impair quality of life (QOL). METHODS: Two pivotal Phase 3 trials explored the effect of setmelanotide on body weight and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kühnen, Peter, Wabitsch, Martin, von Schnurbein, Julia, Chirila, Costel, Mallya, Usha G., Callahan, Patrick, Gnanasakthy, Ari, Poitou, Christine, Krabusch, Philipp M., Stewart, Murray, Clément, Karine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817523/
https://www.ncbi.nlm.nih.gov/pubmed/35123544
http://dx.doi.org/10.1186/s13023-022-02186-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817523/
https://www.ncbi.nlm.nih.gov/pubmed/35123544
http://dx.doi.org/10.1186/s13023-022-02186-z

Ejemplares similares